Focus Partners Wealth’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12M Sell
74,545
-6,720
-8% -$1.12M 0.01% 656
2026
Q2
$15.4M Buy
81,265
+12,315
+18% +$2.32M 0.02% 580
2026
Q1
$13.6M Buy
68,950
+4,999
+8% +$964K 0.02% 619
2025
Q4
$11.6M Buy
63,951
+12,853
+25% +$2.25M 0.01% 655
2025
Q3
$7.89M Buy
51,098
+9,576
+23% +$1.45M 0.01% 626
2025
Q2
$5.8M Buy
41,522
+1,702
+4% +$239K 0.01% 635
2025
Q1
$5.85M Buy
39,820
+4,799
+14% +$694K 0.01% 587
2024
Q4
$4.59M Buy
35,021
+3,367
+11% +$471K 0.01% 634
2024
Q3
$4.92M Buy
31,654
+9,383
+42% +$1.51M 0.02% 565
2024
Q2
$3.47M Buy
22,271
+2,549
+13% +$384K 0.01% 560
2024
Q1
$2.67M Buy
19,722
+5,037
+34% +$667K 0.02% 435
2023
Q4
$1.98M Buy
+14,685
New +$1.91M 0.03% 356

Other funds holding AZN

Focus Partners Wealth's AZN Position: Q3 2026 in Review

Focus Partners Wealth reduced its AstraZeneca (AZN) stake by 8.3% in Q3 2026, selling an estimated $1.12M and leaving 74,545 shares worth $12M. The position accounts for 0.01% of the portfolio, ranked #656.

Focus Partners Wealth first reported a position in AZN in Q4 2023 and has held it in 12 quarters since. The position peaked at $15.4M in Q2 2026. 1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Focus Partners Wealth held 74,545 shares of AstraZeneca worth $12M as of Q3 2026.
  • Focus Partners Wealth sold 6,720 AstraZeneca shares in Q3 2026, an estimated $1.12M.
  • AstraZeneca made up 0.01% of Focus Partners Wealth's portfolio in Q3 2026, its #656 holding.
  • Focus Partners Wealth first reported a position in AstraZeneca in Q4 2023 and has held it in 12 quarters since.
  • Focus Partners Wealth's AstraZeneca position peaked at $15.4M in Q2 2026.
  • 1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Focus Partners Wealth's 13F filing for Q3 2026, filed 12 Nov 2026.